{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:25:00Z","timestamp":1787243100670,"version":"build-2736575974"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jgar.2021.11.011","type":"journal-article","created":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T02:39:16Z","timestamp":1638931156000},"page":"527-533","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["In vitro activity of ceftolozane\/tazobactam against Gram\u2010negative isolates collected from ICU patients with lower respiratory tract infections in seven Asian countries\u2014SMART 2017\u20132019"],"prefix":"10.1016","volume":"29","author":[{"given":"Sibylle H.","family":"Lob","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystyna M.","family":"Kazmierczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fakhar","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5942-9707","authenticated-orcid":false,"given":"C. Andrew","family":"DeRyke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3142-8475","authenticated-orcid":false,"given":"Mary R.","family":"Motyl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Sahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2021.11.011_sbref0001","series-title":"Antimicrobial resistance","year":"2020"},{"key":"10.1016\/j.jgar.2021.11.011_bib0002","series-title":"ZERBAXA (ceftolozane\/tazobactam) for injection, for intravenous use. Package insert","year":"2020"},{"key":"10.1016\/j.jgar.2021.11.011_bib0003","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s10096-018-3274-y","article-title":"Activity of ertapenem against Enterobacteriaceae in seven global regions\u2014SMART 2012\u20132016","volume":"37","author":"Lob","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2021.11.011_bib0004","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.clinthera.2011.11.023","volume":"34","author":"Bertrand","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.jgar.2021.11.011_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.00042-16","article-title":"Carbapenem-resistant Acinetobacter baumannii and Enterobacteriaceae in South and Southeast Asia","volume":"30","author":"Hsu","year":"2017","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2021.11.011_bib0006","doi-asserted-by":"crossref","first-page":"ofy241","DOI":"10.1093\/ofid\/ofy241","article-title":"Carbapenem-nonsusceptible Gram-negative pathogens in ICU and non-ICU settings in US hospitals in 2017: a multicenter study","volume":"5","author":"McCann","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2021.11.011_bib0007","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.diagmicrobio.2013.11.025","article-title":"Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009\u20132011)","volume":"78","author":"Sader","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2021.11.011_bib0008","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jgar.2019.07.017","article-title":"Activity of ceftolozane\u2013tazobactam and comparators against Pseudomonas aeruginosa from patients in different risk strata\u2014SMART United States 2016\u20132017","volume":"20","author":"Lob","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2021.11.011_bib0009","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jgar.2018.05.017","article-title":"Activity of imipenem\/relebactam against Gram-negative bacilli from global ICU and non-ICU wards: SMART 2015\u20132016","volume":"15","author":"Lob","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2021.11.011_bib0010","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.diagmicrobio.2018.04.012","volume":"92","author":"Sader","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2021.11.011_sbref0011","series-title":"Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics","year":"2017"},{"key":"10.1016\/j.jgar.2021.11.011_bib0012","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s13756-019-0654-8","article-title":"Antimicrobial resistance in the Asia Pacific region: a meeting report","volume":"8","author":"Yam","year":"2019","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.jgar.2021.11.011_bib0013","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","year":"2018"},{"key":"10.1016\/j.jgar.2021.11.011_bib0014","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2020"},{"key":"10.1016\/j.jgar.2021.11.011_bib0015","series-title":"Breakpoint tables for interpretation of MICs and zone diameters. Version 10.0, 2020","year":"2020"},{"key":"10.1016\/j.jgar.2021.11.011_bib0016","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jgar.2015.05.005","article-title":"Antimicrobial resistance and resistance mechanisms of Enterobacteriaceae in ICU and non-ICU wards in Europe and North America: SMART 2011\u20132013","volume":"3","author":"Lob","year":"2015","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2021.11.011_bib0017","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1128\/AAC.00220-16","article-title":"In vitro susceptibility of global surveillance isolates of Pseudomonas aeruginosa to ceftazidime\u2013avibactam (INFORM 2012 to 2014)","volume":"60","author":"Nichols","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.11.011_bib0018","doi-asserted-by":"crossref","first-page":"e01822","DOI":"10.1128\/mBio.01822-19","article-title":"Dynamic emergence of mismatch repair deficiency facilitates rapid evolution of ceftazidime\u2013avibactam resistance in Pseudomonas aeruginosa acute infection","volume":"10","author":"Khil","year":"2019","journal-title":"mBio"},{"key":"10.1016\/j.jgar.2021.11.011_bib0019","doi-asserted-by":"crossref","first-page":"e01183","DOI":"10.1128\/AAC.01183-17","article-title":"Emergence of ceftolozane\u2013tazobactam-resistant Pseudomonas aeruginosa during treatment is mediated by a single AmpC structural mutation","volume":"61","author":"MacVane","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.11.011_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105883","article-title":"Activity of ceftolozane\u2013tazobactam against Gram-negative pathogens isolated from lower respiratory tract infections in the Asia-Pacific region: SMART 2015\u20132016","volume":"55","author":"Kuo","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2021.11.011_bib0021","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1099\/jmm.0.000421","article-title":"Antimicrobial susceptibility of Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia\u2013Pacific countries: SMART 2013\u20132015","volume":"66","author":"Karlowsky","year":"2017","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.jgar.2021.11.011_bib0022","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ijantimicag.2017.09.016","volume":"51","author":"Pfaller","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2021.11.011_bib0023","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1128\/JCM.02316-16","article-title":"In vitro activity of imipenem against carbapenemase-positive Enterobacteriaceae isolates collected by the SMART global surveillance program from 2008 to 2014","volume":"55","author":"Karlowsky","year":"2017","journal-title":"J Clin Microbiol"},{"issue":"Suppl 7","key":"10.1016\/j.jgar.2021.11.011_bib0024","doi-asserted-by":"crossref","first-page":"S521","DOI":"10.1093\/cid\/ciz824","article-title":"Epidemiology and diagnostics of carbapenem resistance in Gram-negative bacteria","volume":"69","author":"Nordmann","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.11.011_bib0025","doi-asserted-by":"crossref","first-page":"e00397","DOI":"10.1128\/AAC.00397-20","article-title":"Metallo-\u03b2-lactamases: structure, function, epidemiology, treatment options, and the development pipeline","volume":"64","author":"Boyd","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.11.011_bib0026","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.3389\/fmicb.2018.02888","article-title":"Carbapenem-resistant Enterobacteriaceae infections: Taiwan aspects","volume":"9","author":"Jean","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jgar.2021.11.011_bib0027","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/jac\/dkx136","article-title":"Activity of ceftolozane\/tazobactam against surveillance and \u2018problem\u2019 Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles","volume":"72","author":"Livermore","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.11.011_bib0028","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/jac\/31.suppl_A.9","article-title":"Determinants of the activity of \u03b2-lactamase inhibitor combinations","volume":"31","author":"Livermore","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.11.011_bib0029","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1093\/jac\/dkq248","article-title":"Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus \u03b2-lactamase-producing Enterobacteriaceae","volume":"65","author":"Livermore","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.11.011_bib0030","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1128\/AAC.04498-14","article-title":"In vitro activity of ceftolozane alone and in combination with tazobactam against extended-spectrum-\u03b2-lactamase-harboring Enterobacteriaceae","volume":"59","author":"Melchers","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.11.011_bib0031","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2174\/1389450116666151001105622","article-title":"B1-metallo-\u03b2-lactamases: where do we stand?","volume":"17","author":"Mojica","year":"2016","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.jgar.2021.11.011_bib0032","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.11.011_bib0033","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00582-2017","volume":"50","author":"Torres","year":"2017","journal-title":"Eur Respir J"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521002642?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521002642?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:58:49Z","timestamp":1761991129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716521002642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":33,"alternative-id":["S2213716521002642"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2021.11.011","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of ceftolozane\/tazobactam against Gram\u2010negative isolates collected from ICU patients with lower respiratory tract infections in seven Asian countries\u2014SMART 2017\u20132019","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2021.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 IHMA. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}